Psoriatic Arthritis
Conference Coverage
Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring
For patients with psoriasis concerned about their outcome if infected with COVID-19, “there is no evidence to support stopping biologics or...
From the Journals
Non-Whites remain sorely underrepresented in phase 3 psoriasis trials
In 62 of 82 phase 3 trials for psoriasis therapies that included ethnoracial data, 85.8% of participants were white.
From the Journals
Guselkumab improvements for psoriatic arthritis persist through 1 year
Results extend previously published 24-week DISCOVER-2 data showing significant improvement over placebo.
Conference Coverage
Study highlights differences between White and Latino patients with psoriasis
Latinos had a higher mean percentage of body surface area involvement in the upper limbs.
From the Journals
Experts assess infection risks for patients on biologics
Different DMARDs “all have fairly similar risks when it comes to ‘classical’ or routine bacterial infections. But when you talk about...
From the Journals
Shingrix effective in older adults with preexisting immune-mediated disorders
The most common immune-mediated disorders in two phase 3 clinical trials of the vaccine were psoriasis, spondyloarthropathy, rheumatoid arthritis...
Supplements
Psoriasis and Psoriatic Arthritis
News from the FDA/CDC
Golimumab approval extended to polyarticular-course JIA and juvenile PsA
The expanded approval to include pediatric indications came as part of a review of a clinical trial mandated by the Pediatric Research Equity Act...
Feature
Pregnancy studies on psoriasis, PsA medications pick up
OTIS has enrolled women with psoriasis and/or psoriatic arthritis in studies of nine medications, most of them biologics.
From the Journals
Study results suggest ustekinumab may trigger acute CV events early in treatment
French researchers urge caution in prescribing drug for high-risk patients.
From the Journals
Biologics for psoriasis may also reduce coronary plaque
Cardiac CT scans reveal a reduction in lipid-rich necrotic core (LRNC) in patients who were receiving biologics.